Abstract
The human paraoxonase gene (HUMPONA) is codominantly expressed as alleles A and G. The A allele codes for glutamine (A genotype) and the G allele for arginine (B genotype) at position 191 of the paraoxonase enzyme. This genetic polymorphism has been suggested to be associated with the predisposition to coronary artery disease (CAD). We investigated the frequency of paraoxonase A and G alleles in 380 well-characterized CAD patients and in 169 controls. The most common genotype in both the patients with CAD (211/380) and in healthy Finnish individuals (87/169) was AA (Gln/Gln). The heterozygous AM (Gln/Arg) genotype was present in 140 of the patients and in 75 controls. The frequency of the A allele was 0.74 in both patients and controls. The genotype distribution between the two groups did not differ (P = 0.12, chi2 test). The genotype distributions were also similar to those reported earlier in other caucasoid populations. In conclusion, we found no association between the Gln-Arg 191 polymorphism of the human paraoxonase gene and coronary artery disease in Finns.
Full Text
The Full Text of this article is available as a PDF (116.6 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Adkins S., Gan K. N., Mody M., La Du B. N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993 Mar;52(3):598–608. [PMC free article] [PubMed] [Google Scholar]
- Hegele R. A., Brunt J. H., Connelly P. W. A polymorphism of the paraoxonase gene associated with variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995 Jan;15(1):89–95. doi: 10.1161/01.atv.15.1.89. [DOI] [PubMed] [Google Scholar]
- Humbert R., Adler D. A., Disteche C. M., Hassett C., Omiecinski C. J., Furlong C. E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet. 1993 Jan;3(1):73–76. doi: 10.1038/ng0193-73. [DOI] [PubMed] [Google Scholar]
- Mackness M. I. 'A'-esterases. Enzymes looking for a role? Biochem Pharmacol. 1989 Feb 1;38(3):385–390. doi: 10.1016/0006-2952(89)90376-6. [DOI] [PubMed] [Google Scholar]
- Nevanlinna H. R. The Finnish population structure. A genetic and genealogical study. Hereditas. 1972;71(2):195–236. doi: 10.1111/j.1601-5223.1972.tb01021.x. [DOI] [PubMed] [Google Scholar]
- Ruiz J., Blanché H., James R. W., Garin M. C., Vaisse C., Charpentier G., Cohen N., Morabia A., Passa P., Froguel P. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995 Sep 30;346(8979):869–872. doi: 10.1016/s0140-6736(95)92709-3. [DOI] [PubMed] [Google Scholar]
- Serrato M., Marian A. J. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995 Dec;96(6):3005–3008. doi: 10.1172/JCI118373. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Syvänen A. C., Sajantila A., Lukka M. Identification of individuals by analysis of biallelic DNA markers, using PCR and solid-phase minisequencing. Am J Hum Genet. 1993 Jan;52(1):46–59. [PMC free article] [PubMed] [Google Scholar]
- Watson A. D., Berliner J. A., Hama S. Y., La Du B. N., Faull K. F., Fogelman A. M., Navab M. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest. 1995 Dec;96(6):2882–2891. doi: 10.1172/JCI118359. [DOI] [PMC free article] [PubMed] [Google Scholar]